Lumasonix is transforming cancer care through early detection. Early detection is well recognized as the single most important factor in saving lives. We are developing the first general cancer screening blood test for shifting cancer treatment to earlier, lower cost and more curable stages.

Tumors shed cells in blood as they grow. The AI powered Lumasonix Blood Test uses our patented photoacoustic and ultrasound technology that individually characterizes each cell to count, classify and profile the circulating tumor cells (CTCs) in the specimen. This reagent free process will be fully automated to annually screen a national population with a low-cost test. Cancers are usually diagnosed late after symptoms develop. The treatment of late stage cancers is difficult, often futile, and imposes huge emotional and economic costs. We will shift cancer care to earlier much more treatable stages, saving lives, and Billions for payers.

Lumasonix logo



Event details

Date: October 5 - 9, 2020

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


24 in total